Table 1.
Characteristics of subjects
| HC (n = 13) | RRMS (n = 12) | P | |
|---|---|---|---|
| Age (years) | 31.08 (10.38) | 42.75 (10.47) | 0.01 |
| Sex (% female) | 61.5 | 75.0 | 0.673a |
| Disease duration (years) | – | 10.75 (8.86) | |
| EDSS | – | 2.29 (1.92) | |
| ROI size (voxels) | 144 (16) | 145 (23) | 0.862 |
| T2 lesion count | – | 12.80 (7.45) | |
| T2 lesion volume (ml) | – | 3.80 (3.47) | |
| Cases with CELs | – | 3b | |
| Treatment type | |||
| No treatment | 13 | 4 | |
| Interferon | – | 4 | |
| Glatiramer | – | 1 | |
| Fingolimod | – | 2 | |
| Alemtuzumab | – | 1 |
Values are mean (standard deviation). Difference in means is by unpaired t test, except in aFisher's exact test. bOne RRMS subject did not have a post‐contrast sequence for detection of CELs. CEL, contrast‐enhancing lesion; EDSS, Expanded Disability Status Score.